{"gene":"WFIKKN2","run_date":"2026-04-28T23:00:23","timeline":{"discoveries":[{"year":2008,"finding":"WFIKKN2 binds mature GDF8/myostatin, myostatin propeptide, and GDF11 with high affinity; structure-function studies on the paralogue WFIKKN1 revealed that the follistatin domain is primarily responsible for binding mature growth factor, while the NTR domain contributes most significantly to interaction with myostatin propeptide — consistent architecture applies to WFIKKN2.","method":"Binding assays, domain deletion/structure-function analysis, SPR","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal binding methods, domain-level structure-function mapping, replicated across paralogues","pmids":["18596030"],"is_preprint":false},{"year":2010,"finding":"WFIKKN2 binds TGFβ1, BMP2, and BMP4 with moderate affinity (Kd ~10⁻⁶ M) by SPR, but does not inhibit their signalling activity in reporter assays; WFIKKN2 inhibits GDF8 and GDF11 biological activity in the nanomolar range, acting as a selective antagonist of GDF8/GDF11 but functioning only as a growth factor binding protein for TGFβ1, BMP2, and BMP4.","method":"Surface plasmon resonance (SPR), reporter gene assays","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1–2 — orthogonal biophysical and cell-based functional assays in same study","pmids":["21054789"],"is_preprint":false},{"year":2013,"finding":"WFIKKN2 (GASP-1) blocks myostatin receptor binding and inhibits mature and semilatent myostatin activity, but is less potent than WFIKKN1 at suppressing semilatent myostatin because WFIKKN2 lacks appreciable affinity for the myostatin propeptide domain — an interaction that WFIKKN1 uses to enhance antagonism of semilatent myostatin.","method":"Reporter assays, receptor-binding assays, comparative binding analysis","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays with mechanistic domain-level explanation, clear differential between paralogues","pmids":["23829672"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of the WFIKKN2 follistatin domain (FSD) solved to 1.39 Å; the FSD directly binds GDF8 and GDF11 and blocks their interaction with the type II receptor ActRIIB; alanine substitution of surface-exposed FSD residues reduced GDF8 antagonism in full-length WFIKKN2, identifying specific residues required for ligand antagonism.","method":"X-ray crystallography, native gel shift, SPR, alanine-scanning mutagenesis, reporter assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure + SPR + mutagenesis + functional assay in a single study","pmids":["30814254"],"is_preprint":false},{"year":2011,"finding":"Structure-function studies confirmed that WFIKKN2 interactions with GDF8 and GDF11 are mediated primarily by the follistatin domain and the NTR domain.","method":"Domain-deletion structure-function analysis","journal":"Biochemical Society transactions","confidence":"Medium","confidence_rationale":"Tier 2 — review/summary of experimental domain mapping, corroborated by multiple other papers","pmids":["21936825"],"is_preprint":false},{"year":2023,"finding":"WFIKKN2 is a secreted ligand for divergent DCC-family receptors (Punc, Nope, Protogenin); it mediates repulsion of mouse peripheral sensory axons through the Nope receptor, and attracts motor axons through a distinct, Nope-independent receptor, establishing WFIKKN2 as a bifunctional axon guidance cue.","method":"Ligand-receptor binding identification, in vivo axon guidance assays in mouse, receptor loss-of-function","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — preprint with in vivo functional and receptor-binding evidence, not yet peer-reviewed","pmids":["37398498"],"is_preprint":true}],"current_model":"WFIKKN2 is a secreted multidomain extracellular protein that acts as a potent antagonist of GDF8 (myostatin) and GDF11 by using its follistatin domain to block type II receptor (ActRIIB) binding and its NTR domain to engage myostatin propeptide, while also binding TGFβ1, BMP2, and BMP4 without inhibiting their signalling; additionally, WFIKKN2 functions as a bifunctional axon guidance cue signalling through divergent DCC-family receptors to repel sensory and attract motor axons."},"narrative":{"teleology":[{"year":2008,"claim":"Identification of WFIKKN2's binding partners and domain architecture established it as a high-affinity antagonist of GDF8/GDF11, with the follistatin domain mediating growth factor binding and the NTR domain contributing to propeptide interactions.","evidence":"SPR, binding assays, and domain-deletion structure-function analysis of WFIKKN1/WFIKKN2 paralogues","pmids":["18596030"],"confidence":"High","gaps":["No structural data for the follistatin domain or its binding interface with GDF8/GDF11","Mechanism of selectivity over other TGF-β family members not yet addressed","In vivo relevance of WFIKKN2 antagonism not demonstrated"]},{"year":2010,"claim":"Demonstration that WFIKKN2 binds TGF-β1, BMP2, and BMP4 but fails to inhibit their signalling resolved the question of ligand selectivity, establishing WFIKKN2 as a selective functional antagonist of GDF8/GDF11 rather than a broad TGF-β pathway inhibitor.","evidence":"SPR for binding affinities combined with reporter gene assays for functional inhibition","pmids":["21054789"],"confidence":"High","gaps":["Molecular basis for why binding to TGF-β1/BMP2/BMP4 does not translate to signalling inhibition is unknown","Physiological role of non-inhibitory binding to BMPs not addressed"]},{"year":2013,"claim":"Comparative analysis with WFIKKN1 revealed that WFIKKN2 is less potent against semilatent myostatin because it lacks significant propeptide affinity, clarifying a functional divergence between the two paralogues.","evidence":"Reporter assays, receptor-binding assays, and comparative binding analysis between WFIKKN1 and WFIKKN2","pmids":["23829672"],"confidence":"High","gaps":["Structural basis for differential propeptide binding between WFIKKN1 and WFIKKN2 unknown","Relative contributions of the two paralogues in vivo not determined"]},{"year":2019,"claim":"Determination of the WFIKKN2 follistatin domain crystal structure and identification of specific surface residues required for GDF8 antagonism provided the first atomic-level mechanistic model for how WFIKKN2 competes with ActRIIB for growth factor binding.","evidence":"X-ray crystallography at 1.39 Å, native gel shift, SPR, alanine-scanning mutagenesis, reporter assay","pmids":["30814254"],"confidence":"High","gaps":["No co-crystal structure of the WFIKKN2 FSD–GDF8 complex to reveal the binding interface directly","Contributions of domains outside the FSD to full-length antagonism incompletely characterized at structural level","No structure for the NTR domain or other domains of WFIKKN2"]},{"year":2023,"claim":"Discovery that WFIKKN2 serves as a secreted ligand for DCC-family receptors and mediates bifunctional axon guidance — repelling sensory axons via Nope and attracting motor axons independently — revealed an unexpected second biological role entirely distinct from TGF-β antagonism.","evidence":"Ligand-receptor binding identification, in vivo axon guidance assays in mouse, receptor loss-of-function (preprint)","pmids":["37398498"],"confidence":"Medium","gaps":["Preprint not yet peer-reviewed; independent replication pending","Identity of the motor axon-attracting receptor not determined","Whether axon guidance and GDF8/GDF11 antagonism functions are coordinated in vivo is unknown"]},{"year":null,"claim":"Key unresolved questions include the atomic structure of the full-length WFIKKN2–GDF8 complex, the molecular basis for functional selectivity (antagonism of GDF8/GDF11 versus non-inhibitory binding of BMPs), and the physiological integration of WFIKKN2's dual roles as a TGF-β family antagonist and axon guidance cue.","evidence":"","pmids":[],"confidence":"High","gaps":["No full-length WFIKKN2–GDF8 co-crystal structure","No in vivo genetic loss-of-function studies in mammals characterizing musculoskeletal phenotype","Mechanism by which WFIKKN2 engages DCC-family receptors structurally undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2,3]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,5]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5]}],"complexes":[],"partners":["GDF8","GDF11","ACVR2B","NOPE","PUNC"],"other_free_text":[]},"mechanistic_narrative":"WFIKKN2 is a secreted multidomain extracellular protein that functions as a potent and selective antagonist of TGF-β family members GDF8 (myostatin) and GDF11. Its follistatin domain directly binds mature GDF8 and GDF11 and blocks their interaction with the type II receptor ActRIIB, as demonstrated by crystal structure determination at 1.39 Å resolution and alanine-scanning mutagenesis identifying specific residues required for antagonism [PMID:30814254, PMID:18596030]. WFIKKN2 also binds TGF-β1, BMP2, and BMP4 with micromolar affinity but does not inhibit their signalling, functioning only as a binding protein for these ligands while selectively antagonizing GDF8/GDF11 in the nanomolar range [PMID:21054789]. Compared to its paralogue WFIKKN1, WFIKKN2 is less effective at inhibiting semilatent myostatin because it lacks appreciable affinity for the myostatin propeptide [PMID:23829672]."},"prefetch_data":{"uniprot":{"accession":"Q8TEU8","full_name":"WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2","aliases":["Growth and differentiation factor-associated serum protein 1","GASP-1","hGASP-1","WAP, follistatin, immunoglobulin, Kunitz and NTR domain-containing-related protein","WFIKKN-related protein"],"length_aa":576,"mass_kda":63.9,"function":"Protease-inhibitor that contains multiple distinct protease inhibitor domains. Probably has serine protease- and metalloprotease-inhibitor activity. Inhibits the biological activity of mature myostatin, but not activin (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q8TEU8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/WFIKKN2","classification":"Not Classified","n_dependent_lines":11,"n_total_lines":1208,"dependency_fraction":0.009105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/WFIKKN2","total_profiled":1310},"omim":[{"mim_id":"616480","title":"KIAA1328 GENE; KIAA1328","url":"https://www.omim.org/entry/616480"},{"mim_id":"610895","title":"WAP, FOLLISTATIN, IMMUNOGLOBULIN, KUNITZ, AND NTR DOMAINS-CONTAINING PROTEIN 2; WFIKKN2","url":"https://www.omim.org/entry/610895"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"choroid plexus","ntpm":1103.3}],"url":"https://www.proteinatlas.org/search/WFIKKN2"},"hgnc":{"alias_symbol":["WFIKKNRP","WFDC20B"],"prev_symbol":[]},"alphafold":{"accession":"Q8TEU8","domains":[{"cath_id":"-","chopping":"48-91","consensus_level":"high","plddt":75.5084,"start":48,"end":91},{"cath_id":"3.30.60.30","chopping":"119-177","consensus_level":"medium","plddt":85.7983,"start":119,"end":177},{"cath_id":"2.60.40.10","chopping":"209-304","consensus_level":"medium","plddt":84.9473,"start":209,"end":304},{"cath_id":"4.10.410.10","chopping":"329-381","consensus_level":"medium","plddt":84.7009,"start":329,"end":381},{"cath_id":"4.10.410.10","chopping":"390-436","consensus_level":"high","plddt":84.3853,"start":390,"end":436},{"cath_id":"2.40.50.120","chopping":"455-574","consensus_level":"high","plddt":87.6457,"start":455,"end":574}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TEU8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TEU8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TEU8-F1-predicted_aligned_error_v6.png","plddt_mean":76.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=WFIKKN2","jax_strain_url":"https://www.jax.org/strain/search?query=WFIKKN2"},"sequence":{"accession":"Q8TEU8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TEU8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TEU8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TEU8"}},"corpus_meta":[{"pmid":"18596030","id":"PMC_18596030","title":"Both WFIKKN1 and WFIKKN2 have high affinity for growth and differentiation factors 8 and 11.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18596030","citation_count":67,"is_preprint":false},{"pmid":"21054789","id":"PMC_21054789","title":"WFIKKN1 and WFIKKN2 bind growth factors TGFβ1, BMP2 and BMP4 but do not inhibit their signalling activity.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/21054789","citation_count":41,"is_preprint":false},{"pmid":"27325460","id":"PMC_27325460","title":"WFIKKN1 and WFIKKN2: \"Companion\" proteins regulating TGFB activity.","date":"2016","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27325460","citation_count":21,"is_preprint":false},{"pmid":"21936825","id":"PMC_21936825","title":"Biological functions of the WAP domain-containing multidomain proteins WFIKKN1 and WFIKKN2.","date":"2011","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/21936825","citation_count":17,"is_preprint":false},{"pmid":"23829672","id":"PMC_23829672","title":"Latent myostatin has significant activity and this activity is controlled more efficiently by WFIKKN1 than by WFIKKN2.","date":"2013","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/23829672","citation_count":17,"is_preprint":false},{"pmid":"30814254","id":"PMC_30814254","title":"Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30814254","citation_count":15,"is_preprint":false},{"pmid":"26197924","id":"PMC_26197924","title":"Effect of variation in ovine WFIKKN2 on growth traits appears to be gender-dependent.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26197924","citation_count":6,"is_preprint":false},{"pmid":"24704001","id":"PMC_24704001","title":"Variation in the ovine WFIKKN2 gene.","date":"2014","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24704001","citation_count":3,"is_preprint":false},{"pmid":"37398498","id":"PMC_37398498","title":"WFIKKN2 is a bifunctional axon guidance cue that signals through divergent DCC family receptors.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37398498","citation_count":1,"is_preprint":false},{"pmid":"41194281","id":"PMC_41194281","title":"WFIKKN2 is secreted and elevated in blood plasma of HER2-positive breast cancer patients - implications in cancer surveillance and recurrence monitoring.","date":"2025","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/41194281","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":5953,"output_tokens":1450,"usd":0.019804},"stage2":{"model":"claude-opus-4-6","input_tokens":4710,"output_tokens":3654,"usd":0.17235},"total_usd":0.192154,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"WFIKKN2 binds mature GDF8/myostatin, myostatin propeptide, and GDF11 with high affinity; structure-function studies on the paralogue WFIKKN1 revealed that the follistatin domain is primarily responsible for binding mature growth factor, while the NTR domain contributes most significantly to interaction with myostatin propeptide — consistent architecture applies to WFIKKN2.\",\n      \"method\": \"Binding assays, domain deletion/structure-function analysis, SPR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal binding methods, domain-level structure-function mapping, replicated across paralogues\",\n      \"pmids\": [\"18596030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"WFIKKN2 binds TGFβ1, BMP2, and BMP4 with moderate affinity (Kd ~10⁻⁶ M) by SPR, but does not inhibit their signalling activity in reporter assays; WFIKKN2 inhibits GDF8 and GDF11 biological activity in the nanomolar range, acting as a selective antagonist of GDF8/GDF11 but functioning only as a growth factor binding protein for TGFβ1, BMP2, and BMP4.\",\n      \"method\": \"Surface plasmon resonance (SPR), reporter gene assays\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — orthogonal biophysical and cell-based functional assays in same study\",\n      \"pmids\": [\"21054789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"WFIKKN2 (GASP-1) blocks myostatin receptor binding and inhibits mature and semilatent myostatin activity, but is less potent than WFIKKN1 at suppressing semilatent myostatin because WFIKKN2 lacks appreciable affinity for the myostatin propeptide domain — an interaction that WFIKKN1 uses to enhance antagonism of semilatent myostatin.\",\n      \"method\": \"Reporter assays, receptor-binding assays, comparative binding analysis\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with mechanistic domain-level explanation, clear differential between paralogues\",\n      \"pmids\": [\"23829672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of the WFIKKN2 follistatin domain (FSD) solved to 1.39 Å; the FSD directly binds GDF8 and GDF11 and blocks their interaction with the type II receptor ActRIIB; alanine substitution of surface-exposed FSD residues reduced GDF8 antagonism in full-length WFIKKN2, identifying specific residues required for ligand antagonism.\",\n      \"method\": \"X-ray crystallography, native gel shift, SPR, alanine-scanning mutagenesis, reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure + SPR + mutagenesis + functional assay in a single study\",\n      \"pmids\": [\"30814254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Structure-function studies confirmed that WFIKKN2 interactions with GDF8 and GDF11 are mediated primarily by the follistatin domain and the NTR domain.\",\n      \"method\": \"Domain-deletion structure-function analysis\",\n      \"journal\": \"Biochemical Society transactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review/summary of experimental domain mapping, corroborated by multiple other papers\",\n      \"pmids\": [\"21936825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"WFIKKN2 is a secreted ligand for divergent DCC-family receptors (Punc, Nope, Protogenin); it mediates repulsion of mouse peripheral sensory axons through the Nope receptor, and attracts motor axons through a distinct, Nope-independent receptor, establishing WFIKKN2 as a bifunctional axon guidance cue.\",\n      \"method\": \"Ligand-receptor binding identification, in vivo axon guidance assays in mouse, receptor loss-of-function\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — preprint with in vivo functional and receptor-binding evidence, not yet peer-reviewed\",\n      \"pmids\": [\"37398498\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"WFIKKN2 is a secreted multidomain extracellular protein that acts as a potent antagonist of GDF8 (myostatin) and GDF11 by using its follistatin domain to block type II receptor (ActRIIB) binding and its NTR domain to engage myostatin propeptide, while also binding TGFβ1, BMP2, and BMP4 without inhibiting their signalling; additionally, WFIKKN2 functions as a bifunctional axon guidance cue signalling through divergent DCC-family receptors to repel sensory and attract motor axons.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"WFIKKN2 is a secreted multidomain extracellular protein that functions as a potent and selective antagonist of TGF-β family members GDF8 (myostatin) and GDF11. Its follistatin domain directly binds mature GDF8 and GDF11 and blocks their interaction with the type II receptor ActRIIB, as demonstrated by crystal structure determination at 1.39 Å resolution and alanine-scanning mutagenesis identifying specific residues required for antagonism [PMID:30814254, PMID:18596030]. WFIKKN2 also binds TGF-β1, BMP2, and BMP4 with micromolar affinity but does not inhibit their signalling, functioning only as a binding protein for these ligands while selectively antagonizing GDF8/GDF11 in the nanomolar range [PMID:21054789]. Compared to its paralogue WFIKKN1, WFIKKN2 is less effective at inhibiting semilatent myostatin because it lacks appreciable affinity for the myostatin propeptide [PMID:23829672].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of WFIKKN2's binding partners and domain architecture established it as a high-affinity antagonist of GDF8/GDF11, with the follistatin domain mediating growth factor binding and the NTR domain contributing to propeptide interactions.\",\n      \"evidence\": \"SPR, binding assays, and domain-deletion structure-function analysis of WFIKKN1/WFIKKN2 paralogues\",\n      \"pmids\": [\"18596030\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structural data for the follistatin domain or its binding interface with GDF8/GDF11\",\n        \"Mechanism of selectivity over other TGF-β family members not yet addressed\",\n        \"In vivo relevance of WFIKKN2 antagonism not demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstration that WFIKKN2 binds TGF-β1, BMP2, and BMP4 but fails to inhibit their signalling resolved the question of ligand selectivity, establishing WFIKKN2 as a selective functional antagonist of GDF8/GDF11 rather than a broad TGF-β pathway inhibitor.\",\n      \"evidence\": \"SPR for binding affinities combined with reporter gene assays for functional inhibition\",\n      \"pmids\": [\"21054789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular basis for why binding to TGF-β1/BMP2/BMP4 does not translate to signalling inhibition is unknown\",\n        \"Physiological role of non-inhibitory binding to BMPs not addressed\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Comparative analysis with WFIKKN1 revealed that WFIKKN2 is less potent against semilatent myostatin because it lacks significant propeptide affinity, clarifying a functional divergence between the two paralogues.\",\n      \"evidence\": \"Reporter assays, receptor-binding assays, and comparative binding analysis between WFIKKN1 and WFIKKN2\",\n      \"pmids\": [\"23829672\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for differential propeptide binding between WFIKKN1 and WFIKKN2 unknown\",\n        \"Relative contributions of the two paralogues in vivo not determined\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Determination of the WFIKKN2 follistatin domain crystal structure and identification of specific surface residues required for GDF8 antagonism provided the first atomic-level mechanistic model for how WFIKKN2 competes with ActRIIB for growth factor binding.\",\n      \"evidence\": \"X-ray crystallography at 1.39 Å, native gel shift, SPR, alanine-scanning mutagenesis, reporter assay\",\n      \"pmids\": [\"30814254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No co-crystal structure of the WFIKKN2 FSD–GDF8 complex to reveal the binding interface directly\",\n        \"Contributions of domains outside the FSD to full-length antagonism incompletely characterized at structural level\",\n        \"No structure for the NTR domain or other domains of WFIKKN2\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that WFIKKN2 serves as a secreted ligand for DCC-family receptors and mediates bifunctional axon guidance — repelling sensory axons via Nope and attracting motor axons independently — revealed an unexpected second biological role entirely distinct from TGF-β antagonism.\",\n      \"evidence\": \"Ligand-receptor binding identification, in vivo axon guidance assays in mouse, receptor loss-of-function (preprint)\",\n      \"pmids\": [\"37398498\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Preprint not yet peer-reviewed; independent replication pending\",\n        \"Identity of the motor axon-attracting receptor not determined\",\n        \"Whether axon guidance and GDF8/GDF11 antagonism functions are coordinated in vivo is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic structure of the full-length WFIKKN2–GDF8 complex, the molecular basis for functional selectivity (antagonism of GDF8/GDF11 versus non-inhibitory binding of BMPs), and the physiological integration of WFIKKN2's dual roles as a TGF-β family antagonist and axon guidance cue.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No full-length WFIKKN2–GDF8 co-crystal structure\",\n        \"No in vivo genetic loss-of-function studies in mammals characterizing musculoskeletal phenotype\",\n        \"Mechanism by which WFIKKN2 engages DCC-family receptors structurally undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GDF8\",\n      \"GDF11\",\n      \"ACVR2B\",\n      \"NOPE\",\n      \"PUNC\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, let me fix the pathway term_id. I used \"GO:0162582\" which is invalid. The correct Reactome term is \"R-HSA-162582\" for Signal Transduction. Let me also reconsider the pathway for discovery 5 - it relates to Developmental Biology (axon guidance).\n\n```json\n{\n  \"mechanistic_narrative\": \"WFIKKN2 is a secreted multidomain extracellular protein that functions as a potent and selective antagonist of TGF-β family members GDF8 (myostatin) and GDF11. Its follistatin domain directly binds mature GDF8 and GDF11 and blocks their interaction with the type II receptor ActRIIB, as demonstrated by crystal structure determination at 1.39 Å resolution and alanine-scanning mutagenesis identifying specific residues required for antagonism [PMID:30814254, PMID:18596030]. WFIKKN2 also binds TGF-β1, BMP2, and BMP4 with micromolar affinity but does not inhibit their signalling, functioning only as a binding protein for these ligands while selectively antagonizing GDF8/GDF11 in the nanomolar range [PMID:21054789]. Compared to its paralogue WFIKKN1, WFIKKN2 is less effective at inhibiting semilatent myostatin because it lacks appreciable affinity for the myostatin propeptide [PMID:23829672].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of WFIKKN2's binding partners and domain architecture established it as a high-affinity antagonist of GDF8/GDF11, with the follistatin domain mediating growth factor binding and the NTR domain contributing to propeptide interactions.\",\n      \"evidence\": \"SPR, binding assays, and domain-deletion structure-function analysis of WFIKKN1/WFIKKN2 paralogues\",\n      \"pmids\": [\"18596030\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structural data for the follistatin domain or its binding interface with GDF8/GDF11\",\n        \"Mechanism of selectivity over other TGF-β family members not yet addressed\",\n        \"In vivo relevance of WFIKKN2 antagonism not demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstration that WFIKKN2 binds TGF-β1, BMP2, and BMP4 but fails to inhibit their signalling resolved the question of ligand selectivity, establishing WFIKKN2 as a selective functional antagonist of GDF8/GDF11 rather than a broad TGF-β pathway inhibitor.\",\n      \"evidence\": \"SPR for binding affinities combined with reporter gene assays for functional inhibition\",\n      \"pmids\": [\"21054789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular basis for why binding to TGF-β1/BMP2/BMP4 does not translate to signalling inhibition is unknown\",\n        \"Physiological role of non-inhibitory binding to BMPs not addressed\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Comparative analysis with WFIKKN1 revealed that WFIKKN2 is less potent against semilatent myostatin because it lacks significant propeptide affinity, clarifying a functional divergence between the two paralogues.\",\n      \"evidence\": \"Reporter assays, receptor-binding assays, and comparative binding analysis between WFIKKN1 and WFIKKN2\",\n      \"pmids\": [\"23829672\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for differential propeptide binding between WFIKKN1 and WFIKKN2 unknown\",\n        \"Relative contributions of the two paralogues in vivo not determined\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Determination of the WFIKKN2 follistatin domain crystal structure and identification of specific surface residues required for GDF8 antagonism provided the first atomic-level mechanistic model for how WFIKKN2 competes with ActRIIB for growth factor binding.\",\n      \"evidence\": \"X-ray crystallography at 1.39 Å, native gel shift, SPR, alanine-scanning mutagenesis, reporter assay\",\n      \"pmids\": [\"30814254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No co-crystal structure of the WFIKKN2 FSD–GDF8 complex to reveal the binding interface directly\",\n        \"Contributions of domains outside the FSD to full-length antagonism incompletely characterized at structural level\",\n        \"No structure for the NTR domain or other domains of WFIKKN2\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that WFIKKN2 serves as a secreted ligand for DCC-family receptors and mediates bifunctional axon guidance — repelling sensory axons via Nope and attracting motor axons independently — revealed an unexpected second biological role entirely distinct from TGF-β antagonism.\",\n      \"evidence\": \"Ligand-receptor binding identification, in vivo axon guidance assays in mouse, receptor loss-of-function (preprint)\",\n      \"pmids\": [\"37398498\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Preprint not yet peer-reviewed; independent replication pending\",\n        \"Identity of the motor axon-attracting receptor not determined\",\n        \"Whether axon guidance and GDF8/GDF11 antagonism functions are coordinated in vivo is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic structure of the full-length WFIKKN2–GDF8 complex, the molecular basis for functional selectivity (antagonism of GDF8/GDF11 versus non-inhibitory binding of BMPs), and the physiological integration of WFIKKN2's dual roles as a TGF-β family antagonist and axon guidance cue.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No full-length WFIKKN2–GDF8 co-crystal structure\",\n        \"No in vivo genetic loss-of-function studies in mammals characterizing musculoskeletal phenotype\",\n        \"Mechanism by which WFIKKN2 engages DCC-family receptors structurally undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GDF8\",\n      \"GDF11\",\n      \"ACVR2B\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}